Literature DB >> 22122920

Porphyrins in urine after administration of 5-aminolevulinic acid as a potential tumor marker.

Masahiro Ishizuka1, Yuichiro Hagiya, Yasuhiro Mizokami, Kanako Honda, Kenji Tabata, Toshiaki Kamachi, Kiwamu Takahashi, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Shun-ichiro Ogura, Ichiro Okura.   

Abstract

BACKGROUND: Tumor markers are commonly used for cancer screening and as indicators of therapeutic effects. Certain types of tumor have been known to produce a variety of porphyrins after 5-aminolevulinic acid (ALA) administration. In this study, porphyrins in tumor-bearing mouse urine were analyzed after oral administration of ALA in order to identify new tumor markers excreted in the urine.
METHODS: Porphyrin concentrations in the urine of tumor-bearing mice were measured after administration of 1.0mg of ALA (approximately 50mgkg(-1)).
RESULTS: Porphyrin concentrations in the urine of tumor-bearing mice increased after administration of ALA. HPLC analysis of the urine revealed the existence of uroporphyrin (UP) and coproporphyrin (CP) in the urine of ALA-treated tumor-bearing mice. Furthermore, at 3h after ALA administration, UP concentrations in the urine of tumor-bearing mice significantly increased compared to those in the urine of normal mice.
CONCLUSION: These results suggest that UP as a precursor of heme detected in the urine of tumor-bearing mice after ALA administration is a potential marker of tumor development.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22122920     DOI: 10.1016/j.pdpdt.2011.04.004

Source DB:  PubMed          Journal:  Photodiagnosis Photodyn Ther        ISSN: 1572-1000            Impact factor:   3.631


  6 in total

1.  Improving contrast enhancement in magnetic resonance imaging using 5-aminolevulinic acid-induced protoporphyrin IX for high-grade gliomas.

Authors:  Junkoh Yamamoto; Shingo Kakeda; Tetsuya Yoneda; Shun-Ichiro Ogura; Shohei Shimajiri; Tohru Tanaka; Yukunori Korogi; Shigeru Nishizawa
Journal:  Oncol Lett       Date:  2016-12-27       Impact factor: 2.967

2.  The effect of iron ion on the specificity of photodynamic therapy with 5-aminolevulinic acid.

Authors:  Maiko Hayashi; Hideo Fukuhara; Keiji Inoue; Taro Shuin; Yuichiro Hagiya; Motowo Nakajima; Tohru Tanaka; Shun-ichiro Ogura
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

3.  Randomized, Prospective Double-Blinded Study Comparing 3 Different Doses of 5-Aminolevulinic Acid for Fluorescence-Guided Resections of Malignant Gliomas.

Authors:  Walter Stummer; Herbert Stepp; Otmar D Wiestler; Uwe Pichlmeier
Journal:  Neurosurgery       Date:  2017-08-01       Impact factor: 4.654

Review 4.  Current status of photodynamic technology for urothelial cancer.

Authors:  Keiji Inoue; Hideo Fukuhara; Shinkuro Yamamoto; Takashi Karashima; Atsushi Kurabayashi; Mutsuo Furihata; Kazuhiro Hanazaki; Hung Wei Lai; Shun-Ichiro Ogura
Journal:  Cancer Sci       Date:  2021-12-02       Impact factor: 6.716

5.  The effects of the heme precursor 5-aminolevulinic acid (ALA) on REV-ERBα activation.

Authors:  Kohei Yamashita; Yuichiro Hagiya; Motowo Nakajima; Masahiro Ishizuka; Tohru Tanaka; Shun-Ichiro Ogura
Journal:  FEBS Open Bio       Date:  2014-03-26       Impact factor: 2.693

6.  Characterization of plasma-derived protoporphyrin-IX-positive extracellular vesicles following 5-ALA use in patients with malignant glioma.

Authors:  Pamela S Jones; Anudeep Yekula; Elizabeth Lansbury; Julia L Small; Caroline Ayinon; Scott Mordecai; Fred H Hochberg; John Tigges; Bethany Delcuze; Alain Charest; Ionita Ghiran; Leonora Balaj; Bob S Carter
Journal:  EBioMedicine       Date:  2019-10-15       Impact factor: 8.143

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.